Premium
A randomized, placebo‐controlled crossover trial of phentermine‐topiramate ER in patients with binge‐eating disorder and bulimia nervosa
Author(s) -
Safer Debra L.,
Adler Sarah,
Sethi Shebani,
Bentley Jason P.,
Toyama Hannah,
Pajarito Sarah,
Najarian Thomas
Publication year - 2020
Publication title -
international journal of eating disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.785
H-Index - 138
eISSN - 1098-108X
pISSN - 0276-3478
DOI - 10.1002/eat.23192
Subject(s) - placebo , phentermine , binge eating , topiramate , crossover study , bulimia nervosa , binge eating disorder , abstinence , medicine , randomized controlled trial , psychology , gastroenterology , eating disorders , psychiatry , weight loss , obesity , alternative medicine , pathology , epilepsy
Open trials suggest phentermine/topiramate ER (PHEN/TPM-ER), food and drug administration (FDA) approved for obesity, has utility for binge eating. With no randomized controlled trials (RCTs) yet performed, this trial aimed to evaluate PHEN/TPM-ERs efficacy and safety in a crossover RCT for patients with binge-eating disorder (BED) or bulimia nervosa (BN).